ArticleEFSA journal. European Food Safety Authority2025
Specific effects on the reproductive function including fertility relevant for cumulative risk assessment of pesticide residues.
Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pesticide Residues in Vegetables: The Potential Risk Assessment of Endocrine and Reproductive Disruptors for Children and Adults.Foods (Basel, Switzerland) · 2026Article
- Pesticide Residues in Fruits: From Surveillance Data to Risk-Based Interpretation and Mitigation.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the 'EFSA-SANTE Action Plan on Cumulative Risk Assessment for pesticides residues', EFSA, with the support of a working group, undertook the identification of specific effects on male and female reproductive function, including fertility, that are considered relevant for grouping pesticide residues and for assessing retrospectively the cumulative risk (CRA) deriving from consumers' dietary exposure. In this first report, two specific effects leading to two correspondent cumulative assessment groups (CAGs) were identified for male reproduction, namely, (1) altered mating performance and (2) decreased fertility. Four distinct CAGs were proposed for grouping chemicals affecting female reproduction: (1) altered mating performance, (2) decreased fertility, (3) altered gestation and (4) altered parturition. EFSA also defined the list of indicators (i.e. toxicological endpoints measurable in regulatory studies) describing each specific effect. Qualitative and quantitative information on these indicators will be collected from the toxicological assessment reports on individual pesticide active substances: indicators will be used to determine the inclusion of prioritised active substances and their metabolites into the respective CAG and to estimate the no observed adverse effect level (NOAEL) and lowest observed adverse effect level (LOAEL) of each chemical in relation to the given specific effect. Additional endpoints (named ancillary findings), not sufficiently informative to define a specific effect but contributing to the overall evidence, will be collected for a limited number of substances identified as risk drivers, based on hazard and exposure considerations, to support the estimation of CAG-membership probabilities. Additional criteria for including active substances into CAGs, the hazard characterisation methodology and the lines of evidence for assessing CAG-membership probabilities are detailed in this report, which was sent for public consultation. The process of data extraction and actual establishment of the CAGs are instead beyond the scope of this report. This part of the CRA process was outsourced and will be dealt with in a separate report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.